Pascal Soriot has an awkward relationship with the UK. Now, the boss of AstraZeneca Plc is contemplating a megadeal with US peer Bristol-Myers Squibb Co. that could shift the British drugmaker’s center of gravity further westwards. It’s a potentially tricky tie-up. But Soriot’s counterintuitive bets have paid off before.
Science Bloomberg Aug 3, 2026